b Tested in sodium chloride 0.9%.
c Tested in both dextrose 5% and sodium chloride 0.9%.
d Tested in sterile water for injection.
e Tested in bacteriostatic sodium chloride 0.9% preserved with benzyl alcohol 0.9%.
f Tested in dextrose 5% in Ringer’s injection, dextrose 5% in Ringer’s injection, lactated, dextrose 5%, Ringer’s injection, lactated, and sodium chloride 0.9%.
g Furosemide 0.5 mL injected in the Y-site port of a running infusion of labetalol hydrochloride in dextrose 5%.
h Tested in dextrose 5% with sodium bicarbonate 0.05 mEq/mL.
i Lyophilized formulation tested.
j Refer to Appendix for the composition of parenteral nutrition solutions. TNA indicates a 3-in-1 admixture, and TPN indicates a 2-in-1 admixture.
k Tested in dextrose 5% in sodium chloride 0.225%.
l Injected via Y-site into an administration set running azithromycin.
m Tested in Ringer’s injection, lactated.
n Test performed using the formulation WITHOUT edetate disodium.
o Tested using premixed nitroglycerin infusion in dextrose 5% with citrate buffer (Baxter Healthcare).
p Piperacillin component. Piperacillin in an 8:1 fixed-ratio concentration with tazobactam.
q Quinupristin and dalfopristin components combined.
r Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.
s Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.
t Ceftazidime component. Ceftazidime in a 4:1 fixed-ratio concentration with avibactam.
u Tested in dextrose 5%, sodium chloride 0.9%, and Ringer’s injection, lactated.
v Test performed using the formulation WITH edetate disodium.
w Sulbactam component. Sulbactam in a 1:1 fixed-ratio concentration with durlobactam.